Cargando…
Untargeted metabolomics yields insight into ALS disease mechanisms
OBJECTIVE: To identify dysregulated metabolic pathways in amyotrophic lateral sclerosis (ALS) versus control participants through untargeted metabolomics. METHODS: Untargeted metabolomics was performed on plasma from ALS participants (n=125) around 6.8 months after diagnosis and healthy controls (n=...
Autores principales: | Goutman, Stephen A, Boss, Jonathan, Guo, Kai, Alakwaa, Fadhl M, Patterson, Adam, Kim, Sehee, Savelieff, Masha Georges, Hur, Junguk, Feldman, Eva L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677469/ https://www.ncbi.nlm.nih.gov/pubmed/32928939 http://dx.doi.org/10.1136/jnnp-2020-323611 |
Ejemplares similares
-
Metabolomics identifies shared lipid pathways in independent amyotrophic lateral sclerosis cohorts
por: Goutman, Stephen A, et al.
Publicado: (2022) -
Composite endpoint for ALS clinical trials based on patient preference: Patient-Ranked Order of Function (PROOF)
por: van Eijk, Ruben P A, et al.
Publicado: (2022) -
Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial
por: Paganoni, Sabrina, et al.
Publicado: (2022) -
Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials
por: Diaz-Manera, Jordi, et al.
Publicado: (2018) -
Clinical features and a mutation with late onset of limb girdle muscular dystrophy 2B
por: Takahashi, Toshiaki, et al.
Publicado: (2013)